Antibodies, Monoclonal, Murine-Derived
"Antibodies, Monoclonal, Murine-Derived" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antibodies obtained from a single clone of cells grown in mice or rats.
| Descriptor ID |
D058846
|
| MeSH Number(s) |
D12.776.124.486.485.114.224.075 D12.776.124.790.651.114.224.075 D12.776.377.715.548.114.224.284
|
| Concept/Terms |
Antibodies, Monoclonal, Murine-Derived- Antibodies, Monoclonal, Murine-Derived
- Murine-Derived Monoclonal Antibodies
- Antibodies, Murine-Derived Monoclonal
- Monoclonal Antibodies, Murine-Derived
- Murine Derived Monoclonal Antibodies
|
Below are MeSH descriptors whose meaning is more general than "Antibodies, Monoclonal, Murine-Derived".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Blood Proteins [D12.776.124]
- Immunoproteins [D12.776.124.486]
- Immunoglobulins [D12.776.124.486.485]
- Antibodies [D12.776.124.486.485.114]
- Antibodies, Monoclonal [D12.776.124.486.485.114.224]
- Antibodies, Monoclonal, Murine-Derived [D12.776.124.486.485.114.224.075]
- Serum Globulins [D12.776.124.790]
- Immunoglobulins [D12.776.124.790.651]
- Antibodies [D12.776.124.790.651.114]
- Antibodies, Monoclonal [D12.776.124.790.651.114.224]
- Antibodies, Monoclonal, Murine-Derived [D12.776.124.790.651.114.224.075]
- Globulins [D12.776.377]
- Serum Globulins [D12.776.377.715]
- Immunoglobulins [D12.776.377.715.548]
- Antibodies [D12.776.377.715.548.114]
- Antibodies, Monoclonal [D12.776.377.715.548.114.224]
- Antibodies, Monoclonal, Murine-Derived [D12.776.377.715.548.114.224.284]
Below are MeSH descriptors whose meaning is more specific than "Antibodies, Monoclonal, Murine-Derived".
This graph shows the total number of publications written about "Antibodies, Monoclonal, Murine-Derived" by people in this website by year, and whether "Antibodies, Monoclonal, Murine-Derived" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 2 | 2 |
| 2004 | 0 | 1 | 1 |
| 2005 | 0 | 2 | 2 |
| 2006 | 0 | 2 | 2 |
| 2007 | 0 | 3 | 3 |
| 2008 | 0 | 3 | 3 |
| 2009 | 0 | 8 | 8 |
| 2010 | 1 | 0 | 1 |
| 2011 | 2 | 9 | 11 |
| 2012 | 4 | 2 | 6 |
| 2013 | 0 | 4 | 4 |
| 2014 | 2 | 4 | 6 |
| 2015 | 1 | 0 | 1 |
| 2017 | 0 | 2 | 2 |
| 2018 | 0 | 1 | 1 |
| 2019 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antibodies, Monoclonal, Murine-Derived" by people in Profiles.
-
Need for risk adjustment in comparative effectiveness and cost-effectiveness studies in r/r follicular lymphoma. Blood Adv. 2023 06 13; 7(11):2494-2495.
-
Targeting Fc?RIIB by antagonistic antibody BI-1206 improves the efficacy of rituximab-based therapies in aggressive mantle cell lymphoma. J Hematol Oncol. 2022 04 11; 15(1):42.
-
Distant cutaneous metastasis of malignant epithelioid mesothelioma. J Cutan Pathol. 2021 Jul; 48(7):902-907.
-
Impact of maintenance rituximab in patients with de novo transformed indolent B cell lymphoma. Leuk Lymphoma. 2020 12; 61(12):2985-2989.
-
A Site of Vulnerability on the Influenza Virus Hemagglutinin Head Domain Trimer Interface. Cell. 2019 05 16; 177(5):1136-1152.e18.
-
Salvage Treatment and Survival for Relapsed Follicular Lymphoma Following Primary Radiation Therapy: A Collaborative Study on Behalf of ILROG. Int J Radiat Oncol Biol Phys. 2019 07 01; 104(3):522-529.
-
First-in-human, phase I study of PF-06647263, an anti-EFNA4 calicheamicin antibody-drug conjugate, in patients with advanced solid tumors. Int J Cancer. 2019 10 01; 145(7):1798-1808.
-
Outcomes After Reduced-Dose Intensity Modulated Radiation Therapy for Gastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma. Int J Radiat Oncol Biol Phys. 2019 06 01; 104(2):447-455.
-
Adjuvant everolimus in high-risk diffuse large B-cell lymphoma: final results from the PILLAR-2 randomized phase III trial. Ann Oncol. 2018 03 01; 29(3):707-714.
-
The impact of the neutrophil:lymphocyte ratio in response and survival of patients with de novo diffuse large B-cell lymphoma. Leuk Res. 2018 04; 67:82-85.